5- ハイドロキシトリプタミンは,尿薬治療に抵抗する高血圧の有効な治療法である可能性があります
Rachel Kram1, Hannah Garver2, Gregory D Fink2
1Department of Physiology, Michigan State University, East Lansing MI 48824.
American journal of physiology. Heart and circulatory physiology
|August 20, 2025
まとめ
セロトニン (5-ヒドロキシトリプトミン,5-HT) は,利尿薬が効かない場合でも,ネズミの血圧を下げます. これは,5HTが高血圧治療に 価値のある補足となる可能性を示唆している.
科学分野:
- 心血管の生理学
- 薬理学について
- 腎臓科
背景:
- セロトニン (5- ヒドロキシトリプタミン,5- HT) は慢性注射中に正常血圧と高血圧のラットの両方で平均血圧 (MAP) を一貫して低下させる.
- ダール・SSネズミは塩に敏感な高血圧のモデルであり,利尿剤に反応しない可能性があります.
研究 の 目的:
- 5HTの血圧低下効果が,利尿剤に耐性のあるダール・SSのオスに維持されるかどうかを調べる.
- 高血圧の補助療法として,特に利尿剤耐性において,5-HTの可能性を評価する.
主な方法:
- 男性のダール・SSネズミは,普通または高塩分 (4% NaCl) の食事を与えられ,継続的なMAPモニタリングのために放射能計を植え付けられました.
- ネズミは,アルゼットミニポンプで1週間の連続注射で5HT (25ug/ kg/ min) を投与された.
- 同時に,ネズミはトリクロルメチアジド (TCM) という尿剤を投与されたか,尿剤を投与しなかった.
主要な成果:
- 5HTとTCMの両方を摂取したマウスは,通常の塩食で,5HTのみを摂取したマウスを比較して,MAPが著しく低下した.
- 5-HTとTCMの両方で治療された高塩分ダイエットのラットは,MAPの最も実質的な減少を示しました.
- 5HTの投与は,通常の塩分ダイエットを受けたネズミの腎臓または肝臓機能に悪影響を及ぼさなかった.
結論:
- 5HTはダール-SSラットにおいて,尿薬と併用しても持続的な低血圧効果を示した.
- これらの発見は,チアジド利尿剤のような標準的な治療に対する抵抗を克服し,高血圧に対する効果的な補足療法として機能することを示唆しています.
- 他の抗高血圧単剤に対する耐性の発達にもかかわらず,5- HTの有効性は持続します.
関連する概念動画
01:23Antidepressant Drugs: MAOIs and Other Agents
344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
38
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
38
01:16Antihypertensive Drugs: Action of Diuretics
871
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
871
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
568
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
568
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505